A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 2, 2004, Pages 188-193

  Yao, Guang Bi ^a   Cui, Zhen Yu ^b   Wang, Bao En ^c   Yao, Ji Lu ^d   Zeng, Min De ^e  

^a Shanghai Jing An Qu Central Hospital   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic hepatitis B; Clinical trial; Hepatitis B virus; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTIC ACID; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHIONINE; PLACEBO; TYROSINE; VIRUS DNA;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CHINA; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DEATH; DIARRHEA; DIZZINESS; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; FATIGUE; GENETIC VARIABILITY; HEADACHE; HEPATITIS B; HEPATOBILIARY DISEASE; HUMAN; HYBRIDIZATION; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; NAUSEA AND VOMITING; NOSE INFECTION; OPEN STUDY; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; THERMOREGULATION; THROAT DISEASE; TONSIL DISEASE; VIRUS INFECTION; VIRUS PNEUMONIA;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 2442640368     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Dai ZC, Qi GM. The epidemiology characteristics of viral hepatitis B. In: Viral hepatitis in China: seroepimiological survey in Chinese population (1992-1995). Beijing: China Sci-Tech Publisher; 1997:39-59.
2. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
3. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
4. Yao GB, Wang BE, Cui ZY, Yao JL, Zeng MD. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J (Engl) 1999;112:387-391.
5. Allen M, Gauther J, Des Lauries M, Bourne EJ, Carick KM, Baldanti F, et al. Two sensitive PCR-based methods for the detection of hepatitis B virus variants associated with reduced susceptibility in lamivudine. J Clin Microbiol 1999;37:3338-3347.
6. Ware JE, Sherbourne CD. The MOS short-form health survey (SF-36). Med Care 1992;30:473-481.
7. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-180.
8. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhance hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33: 1527-1532.
9. Petrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Shalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-194.
10. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806.
11. Leung NWY, Liaw YF, Chang TT, Guan R, Lee CM, Ng KY, et al. Durable HBeAg response in Chinese patients treated lamivudine. Hepatology 2001;34:A705.
12. Hong SP, Han KH, Ahn SH, Paik YH, Yoon CC, Moon YM. Additional lamivudine therapy after HBeAg seroconversion would prolong the durability of response in HBV endermic area. Hepatology 2001;34:A600.
13. Yao GB. YMDD mutation in Chinese patients following lamivudine therapy for chronic hepatitis B infection. Gastroenterology 1999;116:A848-A849 (Abstract G3689).
14. Yao GB, Yang MY. The impact of YMDD mutation of HBV during lamivudine treatment and its management. Chin Hepatol 1999;4:194-196.
15. Leung NWY, Lai CL, Guan R, Liaw YF. The effect of long duration of harboring lamivudine-resistant hepatitis B virus (YMDD) mutants on liver histology during 3 years lamivudine therapy in Chinese patients. Hepatology 2001;34:A706.
16. Zhu M, Yao GB, Qian YH. Efficacy of long-term lamivudine therapy after emergency of YMDD mutation in chronic hepatitis B. Chin Hepatol 2002;7:82-86.